Trajenta

Type: Product

Name: Trajenta

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma companyGermany's tough approach to assessing the cost-effectiveness of medicines is threatening the future of research in the country, according to Boehringer Ingelheim.Speaking at the company's annual ... [Published PMLive - Apr 25 2013]

Entities: Trajenta, drug reimbursement, Germany

First reported Apr 16 2013 - Updated Apr 16 2013 - 2 reports

Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level

Home » Blogs » Related Biotechnology, Pharmaceutical and Healthcare NewsBoehringer Ingelheim’s first diabetes product, Trajenta, has been approved in China. It enters China as the fourth DPP-4, but it may not have far to catch up given the reimbursement ... [Published BioPortfolio - Apr 16 2013]

Entities: Trajenta, DPP-4, China, Biotechnology, Health Care

First reported Dec 05 2012 - Updated Dec 05 2012 - 1 reports

Human medicines European Public Assessment Report (EPAR): Trajenta, linagliptin, Revision: 2, Authorised

[Published Pending EC decisions and European Public Assess ... - Dec 05 2012]

Entities: Trajenta, Linagliptin

Quotes

"We have such a robust pipeline that we expect to have the broadest portfolio in our industry. With our late-stage development, we are present across the continuum" Enrique Conterno, the head of Lilly's diabetes business, told Reuters in an interview

Lilly broadens diabetes offer with eye on bigger slice of booming market [Published Reuters - May 03 2013]

More From BioPortfolio on "Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level"

Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level [Published BioPortfolio - Apr 16 2013]

...Physician at the Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland and Principal Investigator of the MARLINA trial. "What is of particular interest is that this study will evaluate the glycaemic efficacy and safety of linagliptin therapy in patients with type 2 diabetes whose kidneys are excreting significant amounts of albumin, a marker of both, kidney damage as well as an overall increased cardiovascular risk."

Boehringer Ingelheim, Lilly begin trial to evaluate use of linagliptin in patients with type 2 di ... [Published PharmaBiz - Mar 21 2013]

More Content

sort by: Date \| Relevance
The First Step in Treating Type 2 Diabetes [Published Motley Fool Discussion Boards - May 10 2013]
Lilly broadens diabetes offer with eye on bigge... [Published Reuters - May 03 2013]
Boehringer: Tough HTA threatens future of Germa... [Published PMLive - Apr 25 2013]
Boehringer’s Trajenta Enters China As DPP-4 Lat... [Published BioPortfolio - Apr 16 2013]
Boehringer’s Trajenta Enters China As DPP-4 Lat... [Published The Rose Sheet - Apr 16 2013]
Boehringer Ingelheim, Lilly begin trial to eval... [Published PharmaBiz - Mar 21 2013]
Boehringer Ingelheim and Lilly initiate MARLINA... [Published Business Wire Health News - Mar 19 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Dec 05 2012]